Board of Directors

Mikael Ørum | Board Chair (since 2015)

Mikael Ørum studied banking, finance and law at the Copenhagen Business College, the Danish Bankers Academy, Copenhagen Business School, and the University of Copenhagen. Mr. Ørum is Chair of RhoVac ApS since 2014, and of RhoVac AB since its establishment in 2015. With more than 35 years' experience in the biotech and finance sectors, Mr. Ørum has participated in the development and implementation of several strategic business plans and has experience in raising capital and international business. He is a founder and partner in Ventac Partners. He has also participated in establishing several successful biotech companies including Exiqon, Santaris Pharma and Avexxin AS, Norway, in which he has held the position of CEO and Board Chair since 2005. He is a part-owner in Ventac Holdings (Cyprus) Ltd., which owns shares in RhoVac.

Cristina Glad | Board Member (since 2015)

Cristina Glad has an Executive MBA and is an entrepreneur with a PhD in Biochemistry. Ms. Glad has more than 25 years' experience in leading biotech industry positions. She has experience in research and business development in the pharmaceutical industry, including with antibodies for diagnostics and therapeutic use, development of production processes for antibody drugs, establishing contract production operations, developing antibody drugs, research and development collaborations with biotech and pharmaceutical companies, and in and out licensing of projects. In her role as CEO and Deputy CEO, Ms. Glad participated in the development of BioInvent International AB from a technology platform to a company with several candidate drugs in their product portfolio. Since December 2013 she has been active as a consultant in her own company. She is a member of The Royal Swedish Academy of Engineering Sciences (IVA).

Lars Hedbys | Board Member (since 2015)

Lars Hedbys has over 30 years' experience in the Life Sciences including 20 years in management positions. Hedbys has an MSc in Chemical Engineering from Chalmers University of Technology and a PhD in Biochemistry from the Faculty of Engineering, Lund University. He has had a long career with Astra Zeneca working in project management, clinical research and development. Mr. Hedbys is CEO of Idogen AB.

Anders Ljungqvist | Board Member (since 2015)

Anders Ljungqvist is a co-founder, CEO, and board member in RhoVac. Mr. Ljungqvist has been a board member in RhoVac ApS since 2008 and in RhoVac AB since its establishment in 2015. He has an MSc in Pharmacy and more than 35 years' experience in the pharmaceutical industry. He has extensive expertise in fields such as project management, product formulation and regulatory issues. As Board Chair, he was involved in the successful exit of SurVac ApS.

Niclas Lundqvist | Board Member (since 2016)

Niclas Lundqvist has a Bachelor of Laws and extensive experience in business law. Since 1996, Lundqvist has specialized as legal counsel in corporate law, and equity exchanges and securities law for companies listed on the Swedish exchanges or MTF. Mr. Lundqvist has experience in operative board activities from his roles as a board member in Swedish listed companies and securities firms supervised by the Finansinspektionen. Previous experience includes working as lawyer, project manager and business developer in Corporate Finance at Sedermera Fondkommission from 2003 to 2013. Lundqvist is a founder of Swedish Growth Fund, a risk capital fund, and is the Board Chair in the parent company Swedish Growth Fund Holding AB.